Organization | ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. Report issue

For profit Phase 2

Founded: San Diego CA United States (2015)

Organization Overview

First Clinical Trial

2021

NCT04930900

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ARS Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (9)

Key: ARS Pharmaceuticals, Inc. (2) Acquired (7)

albuterol (proventil) (1 trial)

capecitabine (xeloda) (1 trial)

epinephrine (levophed) (3 trials)

fam-trastuzumab deruxtecan-nxki (Enhertu) (1 trial)

pembrolizumab (keytruda) (2 trials)

sbt6050 (2 trials)

sbt6290 (1 trial)

trastuzumab (herceptin) (1 trial)

tucatinib (Tukysa) (1 trial)

Indications

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 9